A treatable-traits approach could help tailor IBD care to each patient by targeting specific biological, comorbid, and psychosocial drivers of disease and quality-of-life impairment, potentially improving how we choose...

People with IBD may be interested because the review describes a probiotic (L. plantarum) and synbiotic approaches that could influence gut inflammation, barrier function, and microbiota—areas directly relevant to IBD...

Targeting STING may reduce inflammatory signaling that contributes to ulcerative colitis; a safer, more potent STING inhibitor could become a new therapeutic approach if later-stage studies confirm benefit and safety.

This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...

A fungal infection (basidiobolomycosis) can closely mimic IBD and lead to surgery unless biopsy with fungal stains and culture are done; early azole therapy enabled medical cure in this case. Clinicians in endemic areas...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Community and awareness. The original article is from pressreader.com.

AI could help identify dietary patterns, predict which patients might benefit from specific nutrition approaches, and provide personalized nutrition support — potentially improving inflammation and gut microbiome...

This research describes a new nanoparticle/hydrogel delivery system that reduced inflammation and helped restore the intestinal barrier in mouse models of ulcerative colitis. It suggests a potential future therapeutic...

This preclinical study reports a new pH-sensitive liposomal formulation that increased intestinal delivery and anti-inflammatory effects of roxadustat in animal models of colitis, which could be relevant to future oral...

This study identifies a specific probiotic–commensal interaction that improved colitis in mice and points to a metabolite (phosphatidylcholine) and metabolic pathway that might help repair the gut barrier — a pathway...

Oxidative stress may help explain some biological drivers of inflammation in Crohn’s disease and ulcerative colitis and could become a target for biomarkers or therapies in the future. Right now, the evidence is...

CMUSE can closely mimic Crohn's disease and may require surgery for diagnosis and symptom relief. Recognizing it can change diagnostic pathways and multidisciplinary management for people with recurrent small-bowel...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Chinese Journal of...

A cross‑trust histopathology MDT helped reclassify diagnoses in a substantial proportion of discussed paediatric IBD cases and occasionally changed management or transition planning, which could affect treatment...

Patients and clinicians often ask whether herbal formulas or plant compounds can help IBD. This preclinical study identifies quercetin and the PI3K–Akt pathway as potential mechanisms, which may guide future research...

The study suggests JAK and TYK2 inhibitors can directly change epithelial inflammatory signaling and proliferation in UC, which may be relevant to healing of the gut lining and how different drugs work beyond immune...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Cureus.

People with ulcerative colitis may be interested because synbiotic approaches aim to change the gut microbiome and intestinal barrier and therefore could become a future therapeutic option or adjunct. The paper...

People with UC who need biologic therapy during conception or pregnancy often face limited evidence about safety and effectiveness; this case suggests ustekinumab may be an option when other drugs fail or are stopped for...

The paper describes a potential new anti-inflammatory/hepatoprotective candidate (a cyanobacterium extract) tested in mouse models of liver injury and IBD — early-stage research that could guide future studies but is not...

The paper suggests that loss of microbial bile acid transformations in IBD reduces activation of the TGR5 receptor, and that lower TGR5 bioactivity correlates with higher inflammatory activity — a potential mechanism...

The study links tissue and blood molecular changes to UC severity, suggesting candidate mechanisms (fibrogenesis, neutrophil activation) that could lead to biomarkers or new therapeutic targets. Understanding severity...

The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...

Fecal calprotectin measured by a point‑of‑care CGICA assay showed high accuracy for identifying colorectal inflammation and IBD in patients with chronic diarrhea, which could help avoid some unnecessary colonoscopies...

This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...

An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from hmpgloballearningnetwork.com.

Earlier use of advanced therapies and less steroid exposure could affect long-term outcomes and side-effect risk for people with newly diagnosed IBD. The study also identifies lower use of advanced therapies among...

If the appendix is a significant source of harmful IgG antibodies in ulcerative colitis, that could help explain why appendectomy sometimes reduces UC risk or severity and might influence future therapies targeting...

This study suggests that older-onset IBD is managed more conservatively and experiences fewer extraintestinal manifestations. Patients and clinicians should be aware that age can influence treatment choices and that...

The study suggests nanoplastic particles can alter intestinal barrier function, goblet cells, mucin secretion, and inflammation-related gene expression in models with genetic susceptibility to Crohn’s disease.

Researchers are exploring new anti‑inflammatory compounds derived from food sources; this study reports a krill‑derived selenium‑chelated peptide that reduced inflammation in cells and improved outcomes in a mouse...

Researchers are exploring targeted nanodelivery of miR-497 to reduce oxidative stress and shift immune cells toward tissue-repairing states — a novel preclinical strategy that could eventually lead to new treatments for...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. Open the original article for the full...

Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.

An obituary noting lifelong Crohn's disease may be of interest to the IBD community because it acknowledges the condition and references donation to a major patient organization. Community members and fundraisers may...

Chronic pain affects many people with IBD even after inflammation is controlled, often limiting daily activities and worsening mental health. Understanding that pain can persist without active inflammation highlights the...

If you have IBD, J&J’s ICOTYDE/TREMFYA‑class program could expand oral IL‑23 treatment options for ulcerative colitis and Crohn’s disease and may have implications for perianal fistulizing Crohn’s disease — an area with...

Patients facing total proctocolectomy may care because the surgical approach can affect the chance of needing to convert to open surgery, how long the operation takes, and the short-term risk of complications like...

Probiotics like Lactobacillus GG are often considered by families of children with Crohn’s disease. If helpful, they could offer a low-risk adjunct that targets the gut microbiome and barrier function. This pilot study...

The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...

The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...

This trial tests an oral integrin α4β7 inhibitor for Crohn’s disease, a new small-molecule approach aiming to block gut-specific immune cell trafficking similar to existing biologic anti‑integrin drugs. If effective and...

Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...

People with Crohn’s disease often have disrupted gut microbiomes; this trial tests a food-based approach (cranberry powder) that could potentially encourage beneficial bacteria and reduce inflammation, which is of direct...

This trial tests two investigational agents (eltrekibart and mirikizumab) for moderate–severe ulcerative colitis, which may offer additional treatment options if proven safe and effective. It’s relevant to people whose...

AI could help make assessments (endoscopy, histology, imaging) more objective and combine complex data to better predict disease course—potentially improving personalized care planning for people with IBD.

This study suggests a specific probiotic strain may help reduce colitis in mice by changing the gut microbiome and boosting host phosphatidylcholine production — a pathway that could be relevant to gut barrier repair in...